Coronaviruses Research in BRICS Countries
SARS-CoV-2 has infected more than 105 million people worldwide. During this pandemic, researchers and clinicians have been working to understand the molecular mechanisms that underpin viral pathogenesis by studying viral–host interactions. Now, with the global rollout of various COVID-19 vaccines—ba...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 electronic resource (168 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993544623504498 |
---|---|
ctrlnum |
(CKB)5720000000008321 (oapen)https://directory.doabooks.org/handle/20.500.12854/84441 (EXLCZ)995720000000008321 |
collection |
bib_alma |
record_format |
marc |
spelling |
Fielding, Burtram C. edt Coronaviruses Research in BRICS Countries Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (168 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier SARS-CoV-2 has infected more than 105 million people worldwide. During this pandemic, researchers and clinicians have been working to understand the molecular mechanisms that underpin viral pathogenesis by studying viral–host interactions. Now, with the global rollout of various COVID-19 vaccines—based on the neutralization of the spike protein using different technologies—viral immunology and cell-based immunity are being investigated. Researchers are also studying how various SARS-CoV-2 genetic mutations will impact the efficacy of these COVID-19 vaccines. At the same time, various antiviral drugs have been identified or repurposed that have potential as anti-SARS-CoV-2 treatments. BRICS (Brazil, Russia, India, China, and South Africa) is the acronym used to associate five major emerging national economies. The BRICS countries are known for their significant influence on regional affairs, including being leaders in scientific and clinical research and innovation. This Special Issue includes researchers from BRICS countries, in particular South Africa, involved in the study of SARS-CoV-2 and COVID-19. Original articles, as well as new perspectives or reviews on the matter, were welcomed. Research in the fields of vaccine studies, pathogenesis, genetic mutations, viral immunology, and antiviral drugs were especially encouraged. English Medicine bicssc Epidemiology & medical statistics bicssc SARS-CoV-2 E484K variant of Interest genomic epidemiology Brazil immunoassay SARS-CoV-2 nucleocapsid protein epitope coverage quantitative antibody binding protein microarray SARS-CoV-2 antibodies humoral response COVID-19 nanotechnology detection treatment breakthrough VRDL Delta and Delta plus variant India vaccine dental aerosol-generating procedures extra-oral suction high-volume evacuation low-volume saliva ejector splatter aerosol convalescent plasma COVID-19 and nanotechnology nanomedicine in South Africa bioinformatics and vaccine development vaccine development in South Africa models different settings intervention strategies NSW coronavirus disease 2019 (COVID-19) severe acute respiratory syndrome coronavirus (SARS-CoV-2) neutralizing antibody (NAb) diabetes corticosteroids reverse zoonosis wildlife COVID-19 testing hospital mortality intubation 3-0365-4028-8 3-0365-4027-X Schäfer, Georgia edt Fielding, Burtram C. oth Schäfer, Georgia oth |
language |
English |
format |
eBook |
author2 |
Schäfer, Georgia Fielding, Burtram C. Schäfer, Georgia |
author_facet |
Schäfer, Georgia Fielding, Burtram C. Schäfer, Georgia |
author2_variant |
b c f bc bcf g s gs |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
Coronaviruses Research in BRICS Countries |
spellingShingle |
Coronaviruses Research in BRICS Countries |
title_full |
Coronaviruses Research in BRICS Countries |
title_fullStr |
Coronaviruses Research in BRICS Countries |
title_full_unstemmed |
Coronaviruses Research in BRICS Countries |
title_auth |
Coronaviruses Research in BRICS Countries |
title_new |
Coronaviruses Research in BRICS Countries |
title_sort |
coronaviruses research in brics countries |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2022 |
physical |
1 electronic resource (168 p.) |
isbn |
3-0365-4028-8 3-0365-4027-X |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT fieldingburtramc coronavirusesresearchinbricscountries AT schafergeorgia coronavirusesresearchinbricscountries |
status_str |
n |
ids_txt_mv |
(CKB)5720000000008321 (oapen)https://directory.doabooks.org/handle/20.500.12854/84441 (EXLCZ)995720000000008321 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Coronaviruses Research in BRICS Countries |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1796648862678515712 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03998nam-a2200877z--4500</leader><controlfield tag="001">993544623504498</controlfield><controlfield tag="005">20231214133133.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202206s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5720000000008321</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/84441</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995720000000008321</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Fielding, Burtram C.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Coronaviruses Research in BRICS Countries</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (168 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">SARS-CoV-2 has infected more than 105 million people worldwide. During this pandemic, researchers and clinicians have been working to understand the molecular mechanisms that underpin viral pathogenesis by studying viral–host interactions. Now, with the global rollout of various COVID-19 vaccines—based on the neutralization of the spike protein using different technologies—viral immunology and cell-based immunity are being investigated. Researchers are also studying how various SARS-CoV-2 genetic mutations will impact the efficacy of these COVID-19 vaccines. At the same time, various antiviral drugs have been identified or repurposed that have potential as anti-SARS-CoV-2 treatments. BRICS (Brazil, Russia, India, China, and South Africa) is the acronym used to associate five major emerging national economies. The BRICS countries are known for their significant influence on regional affairs, including being leaders in scientific and clinical research and innovation. This Special Issue includes researchers from BRICS countries, in particular South Africa, involved in the study of SARS-CoV-2 and COVID-19. Original articles, as well as new perspectives or reviews on the matter, were welcomed. Research in the fields of vaccine studies, pathogenesis, genetic mutations, viral immunology, and antiviral drugs were especially encouraged.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Epidemiology & medical statistics</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SARS-CoV-2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">E484K</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">variant of Interest</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genomic epidemiology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Brazil</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunoassay</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SARS-CoV-2 nucleocapsid protein</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epitope coverage</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">quantitative antibody binding</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">protein microarray</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SARS-CoV-2 antibodies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">humoral response</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">COVID-19</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanotechnology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">detection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">breakthrough</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">VRDL</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Delta and Delta plus variant</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">India</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vaccine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dental aerosol-generating procedures</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">extra-oral suction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">high-volume evacuation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">low-volume saliva ejector</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">splatter</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">aerosol</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">convalescent plasma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">COVID-19 and nanotechnology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanomedicine in South Africa</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bioinformatics and vaccine development</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vaccine development in South Africa</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">models</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">different settings</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">intervention strategies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NSW</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">coronavirus disease 2019 (COVID-19)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">severe acute respiratory syndrome coronavirus (SARS-CoV-2)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">neutralizing antibody (NAb)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">diabetes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">corticosteroids</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">reverse zoonosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">wildlife</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">COVID-19 testing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hospital mortality</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">intubation</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4028-8</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4027-X</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schäfer, Georgia</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fielding, Burtram C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schäfer, Georgia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:43:46 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-07-02 22:45:44 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337729600004498&Force_direct=true</subfield><subfield code="Z">5337729600004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337729600004498</subfield></datafield></record></collection> |